secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2022-07-25T23:59:59+00:00
Accession:  0001193125-22-200429
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo to acquire Bayer's agricultural biologics R&D platform for ~$83M
-----------------------------------------------------------------------

- Ginkgo acquires Bayer's 175,000 sq ft West Sacramento Biologics R&D site and team for ~$83M in cash or stock.
- Three-year strategic partnership with Bayer on nitrogen fixation, crop protection, and carbon sequestration.
- Ginkgo to also integrate Joyn Bio R&D platform assets; deal expected to close Q4 2022.
- Ginkgo may earn royalties on net sales from products developed under the Bayer collaboration.
- Expands Ginkgo's agricultural biologicals platform; cash proceeds from collaboration offset acquired expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000119312522200429/0001193125-22-200429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000119312522200429/d368669d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-200429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer